By regulating ECM organization and cell-signalling pathways such as TGFβ, epiphycan may enhance tumour invasiveness and influence patient outcomes, reinforcing its potential as a stromal-associated biomarker and therapeutic target in advanced BC. Here, TGFB1 is linked to neoplasm.